compounding pharmacy phoenix semaglutide Demand Rising for 'Bootlegged' Weight-Loss Drug Compounding Pharmacy Semaglutide: Deep Dive

According to clinical data, between 20 and 50 percent of GLP-1 users report nausea or early fullness, especially in the first months of treatment

Ramphal, 1990

Data in weight loss Most of the existing empirical data on weight loss with GLP-1 agonists come from studies of individuals who are overweight or obese, with or without type 2 diabetes, rather than from studies using these agents to counteract iatrogenic weight gain

Those are small changes on average, yet they are consistent enough across multiple trials to suggest a real, if modest, effect in specific groups and dosing ranges

Sources van Bloemendaal, L, J S ten Kulve, S E la Fleur, R G Ijzerman, and M Diamant

Diarrhea can persist in a small number of cases